SubsidieMeestersDevelopment of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders
ReST Therapeutics aims to develop FENM, a novel NMDA receptor-targeting therapy for PTSD and Alzheimer's, with plans for clinical trials and expanding its drug pipeline by 2027.
Projectdetails
Introduction
ReST Therapeutics is a French biotech company founded in late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms, followed by Alzheimer Disease (AD).
Lead Candidate
Our lead candidate, FENM, is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs.
FENM will enter First-in-Human trials in June 2023 to initiate the clinical demonstration on PTSD.
Future Developments
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders.
With the EIC support, ReST will:
- Bring FENM to clinical Proof of Concept (PhIIb) by 2027.
- Secure a partnership with a pharma company.
- Develop new small molecules to expand its pipeline.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.491.062 |
| Totale projectbegroting | € 3.558.661 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 30-4-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- REST THERAPEUTICSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS DISORDER AND OTHER MENTAL DISORDERSGrayMatters aims to treat PTSD using a non-invasive, machine-learning-based EEG-Neurofeedback device to help patients control amygdala activity, showing promising clinical results. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS DISORDER AND OTHER MENTAL DISORDERS
GrayMatters aims to treat PTSD using a non-invasive, machine-learning-based EEG-Neurofeedback device to help patients control amygdala activity, showing promising clinical results.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transient inactivation of hypothalamic hormone release to prevent post-traumatic stress sensitizationThe project aims to develop small-molecule inhibitors targeting stress-related neurocircuits to create a novel pharmacotherapy for PTSD. | ERC Proof of... | € 150.000 | 2022 | Details |
Neuroregenerative peptide treatment for multiple sclerosisREGENERA MS aims to evaluate a novel peptide's feasibility as a cost-effective, neurorestorative treatment for multiple sclerosis, potentially improving patient outcomes and reducing socioeconomic burdens. | ERC Proof of... | € 150.000 | 2024 | Details |
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSISREGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue. | ERC Proof of... | € 150.000 | 2022 | Details |
DRUG-ELUTING ELECTRICAL IMPLANT TO REPAIR THE SPINAL CORDDREIMS aims to advance a novel drug-eluting electrical implant for spinal cord repair by refining its design and meeting regulatory standards for human therapeutic use. | EIC Transition | € 2.494.542 | 2023 | Details |
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's DiseaseThe NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models. | ERC Proof of... | € 150.000 | 2022 | Details |
Transient inactivation of hypothalamic hormone release to prevent post-traumatic stress sensitization
The project aims to develop small-molecule inhibitors targeting stress-related neurocircuits to create a novel pharmacotherapy for PTSD.
Neuroregenerative peptide treatment for multiple sclerosis
REGENERA MS aims to evaluate a novel peptide's feasibility as a cost-effective, neurorestorative treatment for multiple sclerosis, potentially improving patient outcomes and reducing socioeconomic burdens.
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSIS
REGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue.
DRUG-ELUTING ELECTRICAL IMPLANT TO REPAIR THE SPINAL CORD
DREIMS aims to advance a novel drug-eluting electrical implant for spinal cord repair by refining its design and meeting regulatory standards for human therapeutic use.
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease
The NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models.